Status:
TERMINATED
COPD Exacerbation Blood and Urine Biomarkers Study
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Alpha-1 Foundation
Conditions:
Chronic Obstructive Pulmonary Disease
Acute Exacerbation Copd
Eligibility:
All Genders
35-80 years
Brief Summary
This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD...
Detailed Description
Chronic obstructive pulmonary disease (COPD), a term describing emphysema and chronic bronchitis, is the third leading cause of death in the United States, with approximately 24 million US adults esti...
Eligibility Criteria
Inclusion
- Diagnosed with COPD (FEV1 \<80% AND FEV1/FVC \< 70%)
- Ages 35-80yrs
Exclusion
- History of Asthma
- Bronchiectasis
- Carcinoma of the bronchus
- Recent COPD exacerbation or pulmonary infection (less than 1 month)
- Other significant respiratory disease
- Pregnancy
Key Trial Info
Start Date :
June 7 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 8 2021
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03823443
Start Date
June 7 2018
End Date
January 8 2021
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032